Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path
This article was originally published in The Tan Sheet
Executive Summary
Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.